David A. Siegel Gritstone Bio, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $1.07 Million - $1.68 Million	-122,700 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $1.24 Million - $2.63 Million	-194,100 Reduced 61.27%	122,700 $1.33 Million
Q2 2021 Aug 16, 2021	BUY	$8.13 - $10.2 $2.12 Million - $2.65 Million	260,200 Added 459.72%	316,800 $2.89 Million
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $230,362 - $1.53 Million	56,600 New	56,600 $534,000
Q4 2020 Feb 16, 2021	SELL	$2.57 - $4.22 $110,510 - $181,460	-43,000 Closed	0 $0

Q3 2020 Nov 16, 2020	BUY	$2.63 - $8.09 $41,817 - $128,631	15,900 Added 58.67%	43,000 $114,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $8.17 $154,199 - $221,407	27,100 New	27,100 $180,000

45.6M

861K

4.52M

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $45.3M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.